Palatin CEO claims ‘a positive study on its face,’ despite dry eye drug's primary endpoint miss

Palatin Technologies has some changes to make for the upcoming trials of the dry eye disease drug PL9643 after the phase 3 MELODY-1 study failed on the main goal of improving a clinical sign of the disorder.